Loading patent…
AssigneePierre Fabre Medicament
InventorsLiliane Goetsch, Alexandra Jouhanneaud
Estimating the term…
The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
The use of a milled homogenate and/or a suspension and/or a cell lysate stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen expressed at the surface of the tumoral cells of said resistant tumor, this tumoral antigen not being expressed at the surface of the tumoral cells of the native tumor from which stems the resistant tumor, this tumoral antigen being possibly involved in the resistance of said tumor resistant to the anti-tumoral compound.
A method for generating in vitro an antibody, or one of its functional fragments directed against a tumoral antigen expressed at the surface of a tumor resistant to at least one anti-tumoral compound, the method comprising a step consisting of immunizing animals directly with a milled homogenate and/or a suspension and/or a cell lysate stemming from said resistant tumor, and a step consisting of selecting antibodies recognizing the resistant tumor and not the native tumor from which the resistant tumor stems.
Dependencies are inferred from the claim text.